Highly sensitive assay for long forms of cardiac troponin T to discriminate between myocardial infarction and atrial fibrillation patients
Tuominen, Tuulia (2023-05-02)
Highly sensitive assay for long forms of cardiac troponin T to discriminate between myocardial infarction and atrial fibrillation patients
(02.05.2023)
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
suljettu
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2023060552516
https://urn.fi/URN:NBN:fi-fe2023060552516
Tiivistelmä
Patients with myocardial infarction (MI) require prompt care, but diagnostic challenges can delay the start of treatment. A commonly used biomarker for MI, cardiac troponin T (cTnT), is released in long forms during a MI from the damaged cardiac muscle to the blood circulation. The commercial cTnT tests used in hospital laboratories detects various forms of cTnT and measures elevated cTnT concentrations in several patient groups. An assay specifically detecting long cTnT forms is better at discriminating MI patients from other patient groups. However, the available long cTnT assay is not sensitive enough. The aim of this thesis project was to develop a highly sensitive assay for long cTnT forms.
Based on two immunoassays previously developed at the University of Turku, a novel immunoassay with a photon upconverting label was developed to detect long forms of cTnT in plasma samples. Preliminary analytical characteristics of the assay were determined. Plasma samples from non-ST-elevated MI (NSTEMI, N=32), end-stage renal disease (ESRD, N=38) and atrial fibrillation (AF, N=41) patients were analysed to evaluate the ability of the assay to distinguish these patient groups.
High assay sensitivity was achieved, based on the preliminary limit of blank (0.2 ng/l), limit of detection (0.4 ng/l) and limit of quantitation (1.8 ng/l, 10% CV). Unlike the commercial cTnT test, the developed long cTnT assay could detect significantly higher concentrations from NSTEMI patients than from both ESRD (p<0.001) and AF patients (p<0.001). This study demonstrates that the specific detection of long cTnT forms could improve MI diagnostics.
Based on two immunoassays previously developed at the University of Turku, a novel immunoassay with a photon upconverting label was developed to detect long forms of cTnT in plasma samples. Preliminary analytical characteristics of the assay were determined. Plasma samples from non-ST-elevated MI (NSTEMI, N=32), end-stage renal disease (ESRD, N=38) and atrial fibrillation (AF, N=41) patients were analysed to evaluate the ability of the assay to distinguish these patient groups.
High assay sensitivity was achieved, based on the preliminary limit of blank (0.2 ng/l), limit of detection (0.4 ng/l) and limit of quantitation (1.8 ng/l, 10% CV). Unlike the commercial cTnT test, the developed long cTnT assay could detect significantly higher concentrations from NSTEMI patients than from both ESRD (p<0.001) and AF patients (p<0.001). This study demonstrates that the specific detection of long cTnT forms could improve MI diagnostics.